Q1 2023 Holdings
Filed 2023-05-12 | 31 holdings | $384.9M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Oncology, Inc.(CGEM) | Common | 230031106 | $78.2M | 7,648,268 | 20.3% |
| Provention Bio Inc(PRVBUSD) | Common | 74374N102 | $28.3M | 1,173,809 | 7.3% |
| Iveric Bio Inc(OPHTEUR) | Common | 46583P102 | $25.4M | 1,045,691 | 6.6% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $23.8M | 1,745,943 | 6.2% |
| Inhibrx, Inc Com(INBXUSD) | Common | 45720L107 | $22.5M | 1,192,281 | 5.8% |
| Intellia Therapeutics, Inc.(NTLA) | Common | 45826J105 | $21.3M | 572,459 | 5.5% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $20.2M | 1,225,634 | 5.2% |
| Geron Corporation(GERN) | Common | 374163103 | $18.2M | 8,401,565 | 4.7% |
| Reata Pharmaceuticals inc(RETAEUR) | Common | 75615P103 | $16.5M | 176,874 | 4.3% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $16.1M | 1,639,849 | 4.2% |
| Iovance Biotherapeutics Inc Com(IOVA) | Common | 462260100 | $16.0M | 2,614,977 | 4.2% |
| Regenxbio Inc.(RGNX) | Common | 75901B107 | $11.7M | 617,671 | 3.0% |
| Verve Therapeutics, Inc | Common | 92539P101 | $11.6M | 803,501 | 3.0% |
| Madrigal Pharmaceuticals inc(MDGL) | Common | 558868105 | $8.7M | 36,038 | 2.3% |
| Travere Therapeutics Inc.(TVTX) | Common | 89422G107 | $7.1M | 313,642 | 1.8% |
| Uniqure N.V.(QURE) | Common | N90064101 | $7.0M | 348,224 | 1.8% |
| Insmed Incorporated(INSM) | Common | 457669307 | $6.8M | 399,192 | 1.8% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $6.2M | 2,388,011 | 1.6% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $5.8M | 360,392 | 1.5% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $5.4M | 247,022 | 1.4% |
| Tcr2 Therapeutics, Inc. | Common | 87808K106 | $5.1M | 3,370,982 | 1.3% |
| Chinook Therapeutics, Inc.(290A) | Common | 16961L106 | $4.6M | 197,806 | 1.2% |
| Axsome Therapeutics, Inc.(AXSM) | Common | 05464T104 | $4.3M | 70,402 | 1.1% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $4.3M | 388,292 | 1.1% |
| Arcutis Biotherapeutics inc(ARQT) | Common | 03969K108 | $2.8M | 254,137 | 0.7% |
| Harpoon Therapeutics, Inc. | Common | 41358P106 | $2.4M | 3,196,707 | 0.6% |
| Phathom Pharmaceuticals inc(PHAT) | Common | 71722W107 | $1.5M | 212,615 | 0.4% |
| Inozyme Pharma Inc. | Common | 45790W108 | $1.3M | 233,728 | 0.3% |
| Oncorus, Inc. | Common | 68236R103 | $817.7K | 2,377,031 | 0.2% |
| Avrobio, Inc. | Common | 05455M100 | $647.9K | 647,918 | 0.2% |
| Black Diamond Therapeutics, Inc.(BDTX) | Common | 09203E105 | $273.8K | 144,888 | 0.1% |